Metagenomi Therapeutics (MGX) Prepaid Assets (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Prepaid Assets of $4.4 million for Q1 2026, down 29.25% year-over-year from $6.2 million in Q1 2025, and down 0.86% quarter-over-quarter from $4.4 million in Q4 2025.
Metagenomi Therapeutics (MGX) Prepaid Assets (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Prepaid Assets for 4 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 29.25% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (down 29.25% YoY), while the FY2025 annual figure was $4.4 million, down 47.19% from the prior year.
- Prepaid Assets fell to $4.4 million in Q1 2026 per MGX's latest filing, from $4.4 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $8.4 million in Q4 2024 and bottomed at $4.4 million in Q1 2026.
- Historically, Prepaid Assets has averaged $5.8 million across 4 years, with a median of $5.9 million in 2024.
- Annual changes were most pronounced in 2024 — Prepaid Assets surged 80.95% — and 2025, when it tumbled 47.19%.
- Metagenomi Therapeutics' Prepaid Assets stood at $4.6 million in 2023, then soared by 80.95% to $8.4 million in 2024, then plunged by 47.19% to $4.4 million in 2025, then retreated by 0.86% to $4.4 million in 2026.
- Business Quant data shows MGX's Prepaid Assets at $4.4 million in Q1 2026, $4.4 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.80 Mn |
| Mar 31, 2026 | 4.40 Mn |
| Dec 31, 2025 | 4.43 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Mar 31, 2025 | 6.21 Mn |
| Dec 31, 2024 | 8.40 Mn |
| Sep 30, 2024 | 7.12 Mn |
| Jun 30, 2024 | 6.01 Mn |
| Mar 31, 2024 | 6.16 Mn |
| Dec 31, 2023 | 4.64 Mn |